Empower Precision Therapies with Innovative Biopsy Testing
Over the past 12 months, liquid biopsy testing has continued to revolutionize diagnostics and personalized medicine; from the integration of AI and automation to elevate liquid biopsy capabilities, to the approval of MRD as an endpoint in Multiple Myeloma.
Cementing its position as the world’s leading forum for liquid biopsy specialists, the 9th Liquid Biopsy for Precision Oncology Summit returns to San Diego in February - with a refreshed agenda providing crucial insights spanning biomarker discovery to commercialization, and each critical step in between.
Whether you're new to the field or a seasoned expert, join over 250 of the industry’s top decision-makers from AstraZeneca, Amgen, Eli Lilly, AbbVie, BLOODPAC, Boundless Bio, and more to ensure you and your team are equipped with the insights and connections needed to effectively integrate liquid biopsies into clinical trials and drive meaningful progress in precision oncology.
BRAND NEW EVENT GUIDE
World-Class Speaker Faculty Includes
Lauren Leiman
Executive Director
BLOODPAC
Veerendra Munugalavadla
Senior Director & Team Lead, Translational Medicine, Hematology R&D
AstraZeneca
Anneleen Daemen
Executive Director, Translational Medicine
ORIC Pharmaceuticals
Olivier Harismendy
VP, Translational Data Science & Computational Biology
Zentalis Pharmaceuticals
Marielana Mata
Senior Director, Clinical Biomarkers
Vividion Therapeutics
Michael Stocum
Chief Executive Officer
Bantam Pharmaceuticals
Who Attends This Meeting?
“The Liquid Biopsy for Precision Oncology Summit is a fantastic event bringing together key stakeholders across the industry. From meeting established or new vendors and learning about the latest advances in liquid biopsy research, to reconnecting with colleagues and learning how they have overcome challenges, this meeting has always delivered.”
Peter Teriete, Senior Director & Head of Lead Discovery, IDEAYA Biosciences
2025 Partners Include
Other Events in the Series
